All > Virginia

IMM2902 for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast Cancer+2 MoreIMM2902 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, IMM2902, to see if it is safe and effective in treating patients with advanced solid tumors that express the HER2 protein.

Eligible Conditions
  • Breast Cancer
  • Advanced Solid Tumors
  • Gastric Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Topical Calcipotriene Ointment
1
Gemcitabine
1
Trastuzumab Deruxtecan

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 48 Weeks

48 Weeks
Dose-Limiting Toxicity (DLT)
Number of patients with Adverse Events（AEs）
dose for expansion (RDE) of IMM2902
maximum tolerated dose (MTD) of IMM2902

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Topical Calcipotriene Ointment
1
Gemcitabine
1
Trastuzumab Deruxtecan

Trial Design

1 Treatment Group

IMM2902
1 of 1

Experimental Treatment

135 Total Participants · 1 Treatment Group

Primary Treatment: IMM2902 · No Placebo Group · Phase 1

IMM2902
Drug
Experimental Group · 1 Intervention: IMM2902 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks

Who is running the clinical trial?

ImmuneOnco Biopharmaceuticals (Shanghai) Co., LtdLead Sponsor
3 Previous Clinical Trials
182 Total Patients Enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Lead Sponsor
4 Previous Clinical Trials
198 Total Patients Enrolled
Cheng Huang, MDStudy DirectorVP，Clinical Development
2 Previous Clinical Trials
166 Total Patients Enrolled
Frank Xiaodong GanStudy DirectorSVP, Clinical Development

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Weighs more than 30 kilograms.
You have HER2-low locally advanced or metastatic gastric/esophageal/GEJ cancer who have progression after 2 or more lines of systemic therapy.
You have HER2 IHC 3+ or HER2 IHC 2+/ISH-positive breast cancer.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top